Sulfonylurea treatment in type 2 diabetes

Kirstin Bester  Joey Ton PharmD  Christina Korownyk MD CCFP

Clinical question
Does treating type 2 diabetes with sulfonylureas affect mortality or cardiovascular (CV) events?

Bottom line
There is a lack of evidence that sulfonylureas reduce CV events or mortality in patients with type 2 diabetes. If anything, sulfonylureas potentially increase CV harm.

Evidence
- Most RCTs of sulfonylureas versus placebo studied hemoglobin A1c (HbA1c) level, not patient outcomes.1-3
- The largest RCT for outcomes (N = 409) lasted about 5 years and compared tolbutamide with placebo4-5.

Evidence
- Most RCTs of sulfonylureas versus placebo studied hemoglobin A1c (HbA1c) level, not patient outcomes.1-3
- The largest RCT for outcomes (N = 409) lasted about 5 years and compared tolbutamide with placebo4-5.

- Both all-cause mortality (14.7% vs 10.2%) and myocardial infarction (13.7% vs 10.7%) were non-significant.
- There was a statistically significant increase in CV mortality (12.7% vs 4.9%; number needed to harm [NNH] = 13).
- Limitations were possible randomization imbalance, smoking not included in baseline characteristics, and use of a first-generation sulfonylurea.

- An RCT (N = 304) over 5 years examined patients with coronary artery disease with a mean HbA1c level of 7.6% and compared glipizide with metformin.6 Glipizide increased composite CV events (35% vs 25%, NNH = 10).
- An RCT (N = 2895) over 4 years (mean HbA1c level of 7.4%) compared glyburide with metformin.7 Differences in all-cause mortality (2.2% vs 2.1%) and total CV events (2.9% vs 4.0%) were non-significant. However, about 40% withdrew after randomization.
- An RCT (N = 3028) of about 5 years compared sulfonylureas with pioglitazone and found no difference in CV events when these were added to metformin.8
- A study of sulfonylureas versus dipeptidyl peptidase 4 inhibitors, both added to metformin, reported CV events as adverse events (3.4% vs 1.5%, NNH = 53).9
- Studies comparing sulfonylureas with other agents were underpowered to find a difference in outcomes.10

Context
- A systematic review of observational studies reported increased CV risk with sulfonylureas; however, multiple confounders limited the conclusion.11
- The UK Prospective Diabetes Study is often cited to support sulfonylureas, but it is confounded by insulin use.12
- Sulfonylureas increase the risk of hypoglycemia and weight gain.13 Hypoglycemic risk increases with renal impairment and increasing doses.13

Implementation
The primary cause of death in patients with diabetes is CV disease.14 Sulfonylureas have been recommended as second-line treatment after metformin owing to evidence for improved glycemic control and low cost. Newer agents have shown evidence of CV benefit in patients with diabetes (most with CV disease), but are much more expensive and long-term effects are uncertain.15-16

Ms Bester is a medical student at the University of Alberta in Edmonton. Dr Ton is Knowledge Translation Expert in the Physician Learning Program in the Department of Family Medicine at the University of Alberta. Dr Korownyk is Associate Professor of the PIER (Patients, Experience, Evidence, Research) group in the Department of Family Medicine at the University of Alberta.

Competing interests
None declared.

The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

References